Electra Therapeutics, Inc. Common stock（ETRA）股票分析ETRAElectra Therapeutics, Inc. Common stock

Electra Therapeutics Inc is a United States-based clinical- stage biotechnology company. The Company is developing therapies that target signal regulatory proteins (SIRP) for the treatment of immunological diseases and cancer. Its ELA026, is a monoclonal antibody that targets SIRP on the cell surface of myeloid and T cells and precisely depletes pathological immune cells.

Electra Therapeutics, Inc. is not a good buy right now due to significant declines in its stock price and lack of positive financial indicators. The stock has fallen 41.93% year-to-date and 24.59% over the last 20 days, indicating a persistent downward trend. Furthermore, the company has a price-to-book ratio of -21.69, which suggests severe financial distress. Without any earnings or positive analyst ratings to support a recovery, the risks outweigh potential rewards.